Pediatric Hematology & Oncology
A section of Children (ISSN 2227-9067).
Section Information
The Pediatric Hematology & Oncology Section accepts articles related to the diagnosis and treatment of benign hematologic conditions, childhood and adolescent cancers, and hematopoietic stem cell transplantation for benign and malignant conditions. Articles can focus on therapy, supportive care, long-term outcomes/survivorship, epidemiology and disease prevention, and the economic impact of these diseases (both on the patient and the health care system). Clinical trials and observational studies (cohort studies, case-control studies) are preferred, but systematic reviews/meta-analyses are also welcome as long as they are methodologically rigorous. Case reports will only be considered if they report on a novel finding with important clinical implications.
- Childhood cancer
- Benign hematology
- Hematopoietic stem cell transplant
- Adolescents
- Survivorship/late effects
- Health economics
- Health services research
- Clinical trials
- Solid tumors
- Brain tumors
- Leukemia and lymphoma
- Thrombosis and hemostasis
- Hemoglobinopathies
- Bone marrow failure syndromes
Editorial Board
Special Issues
Following special issues within this section are currently open for submissions:
- Hematologic Diseases in Children: Focus on Genetics and Precision Medicine (Deadline: 10 December 2024)
- Integrative Medicine Approaches in Children and Adolescents with Cancer (Deadline: 15 December 2024)
- Children with Leukemia and Lymphoma: Diagnosis and Management (Deadline: 25 December 2024)
- Pediatric Blood Diseases and Blood Transfusion Treatment (Deadline: 15 January 2025)
- Research Progress in Pediatric Lymphoma (Deadline: 5 March 2025)
- Children with Cancer Diseases: The Present and a Challenge for Future (Deadline: 20 March 2025)
- Advances in Molecular Research in Pediatric Hematology (Deadline: 25 March 2025)
- The Diagnosis and Management of Pediatric Leukemia (Deadline: 30 April 2025)
